Your Health: Simple steps to a better you.

In a groundbreaking development, a new drug prototype named NZ-97 has emerged as a potential game-changer in the treatment of pulmonary diseases. A recent proof-of-concept study published in the Proceedings of the National Academy of Sciences has unveiled promising data indicating NZ-97's ability to stimulate the growth of lung stem cells, offering hope for the regeneration of damaged lung tissue. (Image source:  THE ROYAL PHARMACEUTICAL SOCIETY'S OFFICIAL JOURNAL ) Led by Michael J. Bollong, PhD, an associate professor at Scripps Research in San Diego, California, the research team utilized innovative drug discovery techniques to identify NZ-97. Leveraging the ReFRAME drug repurposing library and database developed by the Calibr-Skaggs Institute for Innovative Medicines, they explored existing drugs as foundations to promote stem cell growth and repair in the lungs. The study focuses on the crucial role of alveolar type 2 cells (AEC2s) in lung regeneration. In various pulmo